PUT - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Real-time Boerse Frankfurt Warrants 14:05:31 2024-05-17 EDT | ||
| 0.46 EUR | -47.13% |
|
| Current month | -90.96% | ||
| 1 month | -90.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.46 | -47.13% |
| 24-05-16 | 0.87 | -14.71% |
| 24-05-15 | 1.02 | -55.26% |
| 24-05-14 | 2.28 | +13.43% |
| 24-05-13 | 2.01 | -22.69% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 02:05 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM9GWP |
| ISIN | DE000VM9GWP8 |
| Date issued | 2024-01-31 |
| Strike | 446.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.24 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.43 € |
|---|---|
| Lowest since issue | 0.46 € |
| Spread | 0.17 € |
| Spread % | 43.59% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Certificates
- Certificat
